Abstract:Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 1010 CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed to better understand probiotic effects on microbiome structure and function and the resulting impacts on CDI.

The clinical applications and prospects of intestinal probiotics on the control of Clostridium difficile-associated diarrhea

Epidemiological and clinical characteristics of Clostridium difficile infection in patients with refractory inflammatory bowel disease

Effect of Probiotics for Prevention of Antibiotic-associated Diarrhea and Clostridium difficile-associated Diarrhea

Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population

Molecular Characterization and Antibiotic Profile of Clostridium Difficile Isolated from Bacteremia

Molecular Characterization and Antibiotic Resistance of Clostridioides Difficile in Patients with Inflammatory Bowel Disease from Two Hospitals in China

Clostridium Butyricumcombined Withbifidobacterium Infantisprobiotic Mixture Restores Fecal Microbiota and Attenuates Systemic Inflammation in Mice with Antibiotic-Associated Diarrhea

Clostridium Butyricum Combined with Bifidobacterium Infantis Probiotic Mixture Restores Fecal Microbiota and Attenuates Systemic Inflammation in Mice with Antibiotic-Associated Diarrhea.

Prevention and treatment of antibiotics-associated adverse effects through the use of probiotics: A review

Modulation of Lactobacillus Rhamnosus GG on the Gut Microbiota and Metabolism in Mice with Clostridioides Difficile Infection

Probiotics: insights and new opportunities for Clostridioides difficile intervention

The Effect of Probiotics on Treatments in Patients Affected by Inflammatory Bowel Disease: A Systematic Review

The New Progresses in the Clinical Application of Probiotics

Protective Effects of Bifidobacterial Strains Against Toxigenic Clostridium Difficile

Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea

Clostridium species as probiotics: potentials and challenges

Consortium of Probiotics Attenuates Colonization of Clostridioides difficile

Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies

Modulatory Effects of Probiotics During Pathogenic Infections With Emphasis on Immune Regulation

Gut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections